Abstract 626P
Background
Circulating tumor DNA (ctDNA) analysis with comprehensive panels is now integral to cancer genomic profiling, advancing precision medicine in clinical practice. Yet, the practicality of treatment post ctDNA testing remains uncertain. This study aims to estimate treatment application post ctDNA analysis and its clinical utility.
Methods
Over a 7-month period, from January to July 2023, we retrospectively evaluated 102 patients with solid tumors who underwent ctDNA using the next generation sequencing method at a university-affiliated tertiary care hospital in Korea. To determine the percentage of genome-driven targeted therapy applied subsequent to ctDNA test result, we employed previously reported FDA-approved companion diagnostic biomarkers and their corresponding drug lists. Cases in which FDA-approved targeted therapy was prescribed or cases in which drugs were changed due to drug resistance after ctDNA testing were assessed.
Results
Out of 102 cases evaluated, 81 cases (79.4%) displayed ctDNA sequencing results featuring actionable variants classified as Tier 1 or Tier II. Among the 73 FDA-approved drugs, 12 were administered at our hospital between January 1, 2023, and July 31, 2023. According to ctDNA results, 21 individuals (20.6% of the total cases) were either prescribed FDA-approved drugs or underwent drug changes. Among them, 15 patients (14.7%) were prescribed FDA-approved drugs, while 6 patients (5.9%) experienced alterations in their medication regimens. Of the 21 patients undergoing targeted therapy based on ctDNA test results, colorectal cancer (12/21, 57.1%) was the most prevalent, followed by NSCLC (4/21, 19.0%). Consistent with these cancer types, the most frequently administered drugs were pembrolizumab (8/21, 38.1%) and cetuximab (6/21, 28.6%).
Conclusions
While this study presents findings from an investigation at a tertiary-hospital in Korea, it underscores the significant prevalence of genome-targeted therapy adoption following ctDNA testing for solid tumors. A larger-scale study should be pursued to further validate these observations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract